Drug Profile
NPC 19
Alternative Names: BK SE36/CpG; BK-SE36; NPC-SE36Latest Information Update: 07 Aug 2023
Price :
$50
*
At a glance
- Originator Osaka University
- Developer BIKEN; Nobelpharma; Osaka University
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Falciparum malaria
Most Recent Events
- 07 Aug 2023 Phase I development is ongoing in Falciparum malaria (In adolescents, In adults, In children, In infants, Prevention) in Burkina Faso (IM) (Nobelpharma pipeline, August 2023)
- 07 Aug 2023 Phase I development is ongoing in Falciparum-malaria (In adolescents, In children, Prevention, In adults) in Uganda (SC) (Nobelpharma pipeline, August 2023)
- 07 Aug 2023 Phase I development is ongoing in Falciparum-malaria (Prevention, In adults) in Japan (IM) (Nobelpharma pipeline, August 2023)